Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: The PROMISE cohort

Diabetes Care

Volumn 38, Issue 5, 2015, Pages 793-800

  Lee, C Christine ^a   Perkins, Bruce A ^b   Kayaniyil, Sheena ^a   Harris, Stewart B ^c   Retnakaran, Ravi ^b,d   Gerstein, Hertzel C ^e   Zinman, Bernard ^b,d   Hanley, Anthony J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICHIGAN NEUROPATHY SCREENING INSTRUMENT; NEUROLOGIC DISEASE; NEUROLOGIC DISEASE ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PREVALENCE; RISK FACTOR; VIBRATION PERCEPTION THRESHOLD; VIBRATION SENSE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERCEPTION; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PREDIABETIC STATE; PROSPECTIVE STUDY; VIBRATION;

ADULT; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE INTOLERANCE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERCEPTION; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS; SENSORY THRESHOLDS; VIBRATION;

EID: 84948718405     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2585     Document Type: Article

References (31)

1. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-1724
2. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20:1162-1167
3. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2002;57:45-51
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. Spijkerman AM, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care 2003;26:2604-2608
6. Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and U.K. Prim Care Diabetes 2014;8:250-255
7. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-819
8. Bongaerts BW, Rathmann W, Kowall B, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care 2012;35:1891-1893
9. Gregg EW, Gu Q, Williams D, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Res Clin Pract 2007;77:485-488
10. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464-469
11. Smith AG. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. J Peripher Nerv Syst 2012;17(Suppl. 2):15-21
12. Hanley AJ, Retnakaran R, Qi Y, et al. Association of hematological parameters with insulin resistance and β-cell dysfunction in nondiabetic subjects. J Clin Endocrinol Metab 2009;94:3824-3832
13. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 2006;108:477-481
14. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289
15. Bril V, Kojic J, Ngo M, Clark K. Comparison of a neurothesiometer and vibration in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997;20:1360-1362
16. Claus D, Mustafa C, Vogel W, Herz M, Neundörfer B. Assessment of diabetic neuropathy: definition of norm and discrimination of abnormal nerve function. Muscle Nerve 1993;16:757-768
17. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999
18. Alberti KG, Eckel RH, Grundy SM, et al, .; International Diabetes Federation Task Force on Epidemiology and Prevention, ; National Heart, Lung, and Blood Institute, ; American Heart Association, ; World Heart Federation, ; International Atherosclerosis Society, ; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
19. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518-523
20. Kelly AS, Steinberger J, Jacobs DR, Hong CP, Moran A, Sinaiko AR. Predicting cardiovascular risk in young adulthood from the metabolic syndrome, its component risk factors, and a cluster score in childhood. Int J Pediatr Obes 2011;6:e283-e289
21. Bril V, Perkins BA. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabet Med 2002;19:661-666
22. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994;17:557-560
23. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-154
24. Cheng YJ, Gregg EW, Kahn HS, Williams DE, De Rekeneire N, Narayan KM. Peripheral insensate neuropathy - a tall problem for US adults? Am J Epidemiol 2006;164:873-880
25. Dyck PJ, Dyck PJ, Klein CJ, Weigand SD. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007;36:536-541
26. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:108-111
27. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig 2011;2:18-32
28. Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol 2007;13:175-191
29. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011;7:682-690
30. Bongaerts BW, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care 2013;36:1141-1146
31. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014;37(Suppl. 1):S14-S80